BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35109668)

  • 1. The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib.
    Yekedüz E; Aktaş EG; Köksoy EB; Doğan N; Ürün Y; Utkan G
    Future Oncol; 2022 Mar; 18(9):1067-1076. PubMed ID: 35109668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
    Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
    Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
    Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
    BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
    Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
    BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
    Angeles A; Hung W; Cheung WY
    Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.
    Del Prete M; Giampieri R; Loupakis F; Prochilo T; Salvatore L; Faloppi L; Bianconi M; Bittoni A; Aprile G; Zaniboni A; Falcone A; Scartozzi M; Cascinu S
    Oncotarget; 2015 Oct; 6(32):33982-92. PubMed ID: 26334693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
    Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
    Miyamoto Y; Schirripa M; Suenaga M; Cao S; Zhang W; Okazaki S; Berger MD; Matsusaka S; Yang D; Ning Y; Baba H; Loupakis F; Lonardi S; Pietrantonio F; Borelli B; Cremolini C; Yamaguchi T; Lenz HJ
    PLoS One; 2020; 15(9):e0239439. PubMed ID: 32970737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
    Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
    Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.
    Del Prete S; Cennamo G; Leo L; Montella L; Vincenzi B; Biglietto M; Andreozzi F; Prudente A; Iodice P; Savastano C; Nappi A; Montesarchio V; Addeo R
    Future Oncol; 2017 Feb; 13(5):415-423. PubMed ID: 27780365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
    Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
    Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong.
    Lam KO; Lee KC; Chiu J; Lee VH; Leung R; Choy TS; Yau T
    Postgrad Med J; 2017 Jul; 93(1101):395-400. PubMed ID: 27836933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
    Abrahao ABK; Ko YJ; Berry S; Chan KKW
    Clin Colorectal Cancer; 2018 Jun; 17(2):113-120. PubMed ID: 29174481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial.
    Pasqualetti G; Schirripa M; Dochy E; Fassan M; Ziranu P; Puzzoni M; Scartozzi M; Alberti G; Lonardi S; Zagonel V; Monzani F; Loupakis F
    Eur J Cancer; 2020 Jul; 133():66-73. PubMed ID: 32446145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study.
    Schirripa M; Pasqualetti G; Giampieri R; Scartozzi M; Lonardi S; Rumanò L; Bergamo F; Stragliotto S; Murgioni S; Alberti G; Rizzato MD; Prete AA; Puzzoni M; Pusceddu V; Ziranu P; Pani F; Mariotti S; Zagonel V; Monzani F; Loupakis F
    Clin Colorectal Cancer; 2018 Sep; 17(3):e601-e615. PubMed ID: 30149875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib: A Review in Metastatic Colorectal Cancer.
    Dhillon S
    Drugs; 2018 Jul; 78(11):1133-1144. PubMed ID: 29943375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
    Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
    Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.